TOKENPOST
1 min read
Add as a preferred source on Google

Harmony Biosciences Shares Fall 7% as Wakix Patent Arguments Unfold

Arguments were underway Thursday in Wilmington, Delaware, in an ANDA patent case involving AET Pharma.

By Enna Lee
Published
Empty courthouse steps lead toward a sunlit stone entrance / TokenPost.ai
Empty courthouse steps lead toward a sunlit stone entrance / TokenPost.ai

Harmony Biosciences Holdings, Inc. (HRMY) shares fell 7% on Oct. 22 as closing arguments were underway in a patent dispute over Wakix, the company’s drug.

The arguments were taking place Thursday in Wilmington, Delaware, in ANDA patent litigation between Harmony and AET Pharma.

Enna Lee

Reporter

Enna Lee reports on investing and digital-asset markets for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…